LGALS3 and diffuse large B-cell lymphoma: When studied as a potential biomarker for the prognosis of DLBCL, elevated levels of galectin-3 have been associated with more aggressive disease and poor prognosis, having a role in promoting tumor cell adhesion to the extracellular matrix, demonstrating anti-apoptotic properties, and being involved in differentiation from follicular lymphoma [58].